UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Obesity as a risk factor for antipsychotic noncompliance

Schizophrenia research, 2004, Vol.66 (1), p.51-57

2004

Volltextzugriff (PDF)

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

BMC psychiatry, 2022-08, Vol.22 (1), p.1-574, Article 574

2022

Volltextzugriff (PDF)

Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia

BMC psychiatry, 2018-09, Vol.18 (1), p.292-292, Article 292

2018

Volltextzugriff (PDF)

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey

BMC psychiatry, 2020-07, Vol.20 (1), p.354-12, Article 354

2020

Volltextzugriff (PDF)

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

BMC psychiatry, 2021-10, Vol.21 (1), p.1-492, Article 492

2021

Volltextzugriff (PDF)

Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis

The American journal of psychiatry, 1999-11, Vol.156 (11), p.1686-1696

1999

Volltextzugriff (PDF)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

BMC psychiatry, 2021-03, Vol.21 (1), p.164-8, Article 164

2021

Volltextzugriff (PDF)

Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic

Trends in pharmacological sciences (Regular ed.), 2022-12, Vol.43 (12), p.1098-1112

2022

Volltextzugriff (PDF)

Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone

The journal of clinical psychiatry, 2017-07, Vol.78 (7), p.e813-e820

2017

Volltextzugriff (PDF)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

CNS spectrums, 2014-08, Vol.19 (4), p.330-339

2014

Volltextzugriff (PDF)

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study

The journal of clinical psychiatry, 2022-05, Vol.83 (3)

2022

Volltextzugriff (PDF)

Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison

Value in health, 2017-07, Vol.20 (7), p.876-885

2017

Volltextzugriff (PDF)

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia

The American journal of psychiatry, 2019-06, Vol.176 (6), p.457-467

2019

Volltextzugriff (PDF)

Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study

The journal of clinical psychiatry, 2020-08, Vol.81 (5)

2020

Volltextzugriff (PDF)

Redefining Medication Adherence in the Treatment of Schizophrenia: How Current Approaches to Adherence Lead to Misinformation and Threaten Therapeutic Relationships

The Psychiatric clinics of North America, 2016-06, Vol.39 (2), p.199-216

Weiden, Peter J

2016

Volltextzugriff (PDF)

How many treatments before clozapine? medication choices across the spectrum of treatment resistance in schizophrenia

The journal of clinical psychiatry, 2016-05, Vol.77 (5), p.e594

Weiden, Peter J

2016

Volltextzugriff (PDF)

Helping Patients With Mental Illness Get Back to Work

The American journal of psychiatry, 2015-09, Vol.172 (9), p.817-819

Weiden, Peter J.

2015

Volltextzugriff (PDF)

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs

The journal of clinical psychiatry, 2013-06, Vol.74 (6), p.568-575

2013

Volltextzugriff (PDF)

Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia

Psychiatric services (Washington, D.C.), 2004-08, Vol.55 (8), p.886-891

2004

Volltextzugriff (PDF)

Understanding Why Muscarinic Receptor Agonists Have Antipsychotic Properties

CNS spectrums, 2022-04, Vol.27 (2), p.249-249

2022

Volltextzugriff (PDF)

Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia

CNS spectrums, 2020-06, Vol.25 (3), p.1-330

2020

Volltextzugriff (PDF)

Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study

The journal of clinical psychiatry, 2020-05, Vol.81 (3)

2020

Volltextzugriff (PDF)

Understanding and addressing adherence issues in schizophrenia: from theory to practice

The journal of clinical psychiatry, 2007, Vol.68 Suppl 14, p.14

Weiden, Peter J

2007

Volltextzugriff (PDF)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

Neuropsychiatric disease and treatment, 2019-09, Vol.15, p.2559-2569

2019

Volltextzugriff (PDF)

Cognitive Behavior Therapy for Schizophrenia

The American journal of psychiatry, 2006-03, Vol.163 (3), p.365-373

2006

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(186)
Berichte
(2)

Sprache

Englisch
(188)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(122)
Science & Technology
(122)
Humans
(113)
Psychiatry
(102)
Schizophrenia
(78)
Schizophrenia - Drug Therapy
(78)
Female
(61)
Adult
(58)
Antipsychotic Agents - Therapeutic Use
(58)
Male
(57)
Antipsychotic Agents - Adverse Effects
(48)
Biological And Medical Sciences
(46)
Medical Sciences
(44)
Psychology. Psychoanalysis. Psychiatry
(37)
Antipsychotics
(35)
Middle Aged
(33)
Treatment Outcome
(32)
Schizophrenic Psychology
(31)
Psychopathology. Psychiatry
(30)
Psychopharmacology
(30)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Obesity as a risk factor for antipsychotic noncompliance

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic

Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study

Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia

Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study

Redefining Medication Adherence in the Treatment of Schizophrenia: How Current Approaches to Adherence Lead to Misinformation and Threaten Therapeutic Relationships

How many treatments before clozapine? medication choices across the spectrum of treatment resistance in schizophrenia

Helping Patients With Mental Illness Get Back to Work

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs

Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia

Understanding Why Muscarinic Receptor Agonists Have Antipsychotic Properties

Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia

Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study

Understanding and addressing adherence issues in schizophrenia: from theory to practice

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

Cognitive Behavior Therapy for Schizophrenia

Suchergebnisse filtern